Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
The Medical Journal of Australia|January 11, 2024
Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort studyLuke S McLean, Annette M Lim, Mathias Bressel, et al.
NPJ Precision Oncology|June 18, 2025
The development of a high-plex spatial proteomic methodology for the characterisation of the head and neck tumour microenvironmentChin Wee Tan, Naomi Berrell, Meg L Donovan, et al.
Cancer Research Communications|February 27, 2025
A Proteomic Signature for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma Predicts Patients at High Risk of RecurrenceChristopher C Jackson, Jia Jenny Liu, Howard Y Liu, et al.
BMC Cancer|August 19, 2021
MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)Ho Wai Derrick Siu, Niall Tebbutt, Lorraine Chantrill, et al.
Clinical Colorectal Cancer|January 8, 2025
AGITG MONARCC: A Randomized Phase 2 Study of Panitumumab Monotherapy and Panitumumab Plus 5-Fluorouracil as First-Line Therapy for Older Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer. A Study by the Australasian Gastro-Intestinal Trials Group (AGITG)Matthew E Burge, David Espinoza, Katrin Marie Sjoquist, et al.
BMJ Open|November 20, 2024
Patient Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience (PROMISE)-protocol for a randomised controlled trial of electronic self-reporting of symptoms versus usual care during and following treatment in patients with cancerPenelope M Webb, Amy Brown, Bena Brown, et al.
Journal for Immunotherapy of Cancer|October 17, 2023
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinomaPhilip Clingan, Rahul Ladwa, Daniel Brungs, et al.
Journal of the American Academy of Dermatology|October 7, 2025
Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ≥2 yearsEmily S Ruiz, Eva Muñoz-Couselo, Henri Montaudié, et al.
The New England Journal of Medicine|June 2, 2025
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell CarcinomaDanny Rischin, Sandro Porceddu, Fiona Day, et al.
Journal of the American Academy of Dermatology|September 8, 2024
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6Brett G M Hughes, Alexander Guminski, Samantha Bowyer, et al.
Pageof 7